Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses promising novel treatment approaches for patients with Waldenström’s macroglobulinemia (WM), including combination approaches with Bruton’s tyrosine kinase (BTK) inhibitors, and non-covalent BTK inhibitors, such as pirtobrutinib and nemtabrutinib. Dr Castillo also highlights the promise of several immunotherapies, including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR-T cell therapy. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.